Fictional patient with COPD holding Trelegy Ellipta inhaler
Start your patients on Trelegy Ellipta today, expect more from their tomorrows⁹⁻¹⁰

A single-inhalation, once-daily COPD triple therapy treatment¹

Trelegy Ellipta is for patients with moderate to severe COPD on treatment with an ICS/LABA (or an ICS/LABA containing treatment) who are symptomatic and at risk of an exacerbation¹⁻³

*Fluticasone furoate and vilanterol are not licensed as monotherapies in COPD.

Who could benefit from Trelegy Ellipta?

Indication | Trelegy Ellipta is indicated for maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting ß₂-agonist (LABA) or a combination of a long-acting ß₂-agonist (LABA) and a long-acting muscarinic antagonist (LAMA).¹

Fictional patient with COPD

Meet Sylvia, she has COPD

She is on treatment with an ICS/LABA (or an ICS/LABA containing treatment) and is symptomatic and at risk of an exacerbation, defined as:

  • Has worsening of symptoms or
  • Has experienced an exacerbation treated
  • with antibiotics or oral corticosteroids in the past 12 months

Learn more about how to spot patients like Sylvia.

How can Trelegy Ellipta benefit your patients with COPD?

See clinical data on Trelegy Ellipta from the FULFIL and IMPACT trials.

COPD Lung Function

Superior lung function improvement:

+171mL improvement from baseline in trough FEV₁ vs. an ICS/LABA at week 24 (p<0.001)*⁹

*(Trelegy OD n=911 vs. Symbicort Turbohaler (BUD/FOR 320/9mcg) BD n=899; +171 mL improvement, +142 mL and -29 mL, respectively; p<0.001)⁹

COPD health related quality of life

Superior quality of life improvement:

1.5x improvement in HRQoL vs. an ICS/LABA at week 24 (p<0.001, ARR 2.2)*⁹

*HRQoL is measured by SGRQ. ARR: 2.2 unit improvement (Trelegy OD n=846 vs Symbicort Turbohaler (BUD/FOR 320/9mcg) BD n=791; -6.6 vs -4.3 units from baseline, respectively). The figures have been rounded from -6.57 and -4.33, respectively). MCID = 4 unit change⁹ ¹⁷

COPD exacerbation reduction

Superior exacerbation rate reduction:

44% reduction in the annual rate of moderate/severe exacerbations vs an ICS/LABA at week 52 in the extension population (p=0.006, ARR: 0.16)*⁹

*ARR: 0.16; 0.20 vs 0.36 respectively (Trelegy Ellipta OD n=210 vs Symbicort Turbohaler BD n=219, an extension population comprised of a subset of the ITT population [n=1810])⁹

COPD hospitalised exacerbations

Superior hospitalised exacerbation rate reduction:

34% reduction in the annual rate of hospitalised exacerbations vs a LAMA/LABA (UMEC/VI) based on data up to 52 weeks (p<0.001, ARR: 0.06)*¹⁰

*ARR: 0.06; 0.13 vs 0.19 respectively (Trelegy Ellipta OD n=4145 vs UMEC/VI n=2069).¹⁰ Anoro Ellipta (umeclidinium bromide/vilanterol) is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)¹⁶

Anoro Ellipta Prescribing Information

  • Trelegy Ellipta safety profile

    Common adverse reactions: headache, nasopharyngitis, influenza, upper respiratory tract infection, pneumonia, back pain, rhinitis, cough, pharyngitis, arthralgia, sinusitis, oropharyngeal pain, bronchitis, constipation, candidiasis of mouth and throat and urinary tract infection¹

    Cardiovascular: cardiovascular effects, such as cardiac arrhythmias (e.g. atrial fibrillation and tachycardia), may be seen after the administration of muscarinic receptor antagonists and sympathomimetics, including umeclidinium and vilanterol, respectively. Therefore, Trelegy Ellipta should be used with caution in patients with unstable or life-threatening cardiovascular disease.¹

    Pneumonia: in common with other corticosteroid-containing medicines, there is an increased risk of pneumonia in patients with COPD treated with Trelegy Ellipta, including pneumonia requiring hospitalisation. There is no conclusive clinical evidence for intra-class differences in the magnitude of the pneumonia risk among inhaled corticosteroid products. Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of such infections overlap with the symptoms of COPD exacerbations. Risk factors for pneumonia in patients with COPD include current smoking, older age, low body mass index and severe COPD.

    This is not an exhaustive list. Please consult the Summary of Product Characteristics for a full list of adverse reactions before prescribing.

Trelegy delivers an ICS, a LABA, and a LAMA in the Ellipta inhaler¹

Could simplified delivery of COPD triple therapy in a single inhaler make a difference for your patient?

How to use the Ellipta inhaler

Easy-to-use Ellipta helps patients get the right dose³⁻⁵

Significantly fewer COPD patients made a critical error* with the Ellipta inhaler compared with other commonly used COPD inhalers after reading the patient information leaflet (p<0.001).⁵

Ellipta DPI vs MDI

Ellipta inhaler has an 18x lower carbon footprint than a pMDI⁷⁻⁸

Ellipta is a propellant-free dry powder inhaler (DPI). The BTS position statement (2020) has provided recommendation on the use of low carbon inhalers where clinically safe and appropriate to do so (BTS only recommends an inhaler device type. It does not endorse specific medicines).⁸

*Critical errors defined as errors that are likely to result in no, or minimal, medication being delivered to the lung. Critical errors: Ellipta vs. Turbohaler (n=100) 8% vs. 44%; Ellipta vs. MDI (n=80) 13% (10/80) vs. 60% (48/80)⁵

Get started with Trelegy Ellipta

Footnotes

BTS, British Thoracic Society; BD, twice daily; BUD, budesonide; CAT, COPD assessment test; DPI, dry powder inhaler; FEV₁, forced expiratory volume in one second; FF, fluticasone furoate; FOR, formoterol; HRQoL, health-related quality of life; ICS, inhaled corticosteroid; ITT, intent-to-treat; LABA, long-acting ß₂-agonist; LAMA, long-acting muscarinic antagonist; OD, once daily; QoL, quality of life; pMDI, pressurised metered dose inhaler; SGRQ, St George’s Respiratory Questionnaire; UMEC, umeclidinium; VI, vilanterol

Trelegy Ellipta OD is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β₂-agonist or a combination of a long-acting β₂-agonist and a long-acting muscarinic antagonist.¹

Trelegy Ellipta is generally well tolerated. Common adverse reactions include: headache, nasopharyngitis, influenza, upper respiratory tract infection, pneumonia, back pain, rhinitis, cough, pharyngitis, arthralgia, sinusitis, oropharyngeal pain, bronchitis, constipation, candidiasis of mouth and throat, urinary tract infection.¹

This is not an exhaustive list. Please consult the Summary of Product Characteristics for a full list of adverse reactions before prescribing.

In common with other corticosteroid-containing medicines, there is an increased risk of pneumonia in patients with COPD treated with Trelegy Ellipta.¹

References

  1. Trelegy Ellipta SmPC
  2. GOLD Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (GOLD), 2020.
  3. Hurst JR et al. N Engl J Med. 2010;363(12):1128-1138.
  4. Svedsater H et al. BMC Pulm Med 2013; 13:1–14.
  5. van der Palen J et al. NPJ Prim Care Respir Med 2016; 26:16079.
  6. Riley JH et al. Int J Chron Obstruct Pulm Dis 2016; 11:1873–1880.
  7. Hillman, T. Mortimer, F and Hopkinson, N. (2013). Inhaled drugs and global warming: time to shift to dry powder inhalers. British Medical Journal. DOI: 10.1136/bmj.f3359.
  8. British Thoracic Society (BTS) (2020) Position Statement: Environment and Lung Health. https://www.brit-thoracic.org.uk/about-us/position-statements/
  9. Lipson DA et al. Am J Respir Crit Care Med 2017; 196:438–446.
  10. Lipson DA et al. N Engl J Med 2018; 378:1671–1680.
  11. Incruse Ellipta (umeclidinium bromide) SmPC Incruse Prescribing Information
  12. Kempsford et al. Pulm Pharmacol Ther. 2013; 26(2): 256-64
  13. Biggadike K et al. J Med Chem 2008; 51: 3349-3352
  14. Salter M et al. Am J Physiol Lung Cell Mol Physiol 2007; 293:L660-L667
  15. Lipson DA et al. Poster no. 372 presented at ATS 2017; Abstract number A3605.
  16. ANORO Ellipta SmPC.
  17. Jones PW J. of COPD, 2005; 2:75-79

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

© 2020 GSK Group of Companies or its licensor
Trademarks are the property of their respective owners
Trelegy Ellipta was developed in collaboration with

PM-GB-FVU-WCNT-200014 | September 2020